

1

1 Title: SARS-CoV-2 vaccine breakthrough by Omicron and Delta variants: comparative assessments with
2 New York State genomic surveillance data

3

4

5 Running Title: Vaccine breakthrough by Omicron vs Delta

6

7 Authors: Alexander C. Keyel^{1*}, Alexis Russell¹, Jonathan Plitnick¹, Jemma V. Rowlands², Eli
8 Rosenberg^{2,3}, Daryl M. Lamson¹, Kathleen A. McDonough^{1,2,3}, and Kirsten St. George^{1,3}

9

10 ¹ Wadsworth Center, New York State Department of Health, Albany, NY, United States of America

11 ² Department of Epidemiology, New York State Department of Health, Albany, NY, United States of
12 America

13 ³ Department of Biomedical Science, University at Albany School of Public Health, State
14 University of New York, Albany, NY, United States of America

15

16 ORCIDs: ACK: 0000-0001-5256-6274, AR: 0000-0002-4252-0552, JP: 0000-0003-3417-8969, JVR:
17 0000-0002-2320-495X, DML: 0000-0002-6497-917X, KSG: 0000-0001-5168-763X

18

19 Main Article Word Count: 3342

20 Abstract Word Count: 187

21

22 Conflict of Interest Statement: ACK, AR, JP, JVR, ER, DML, and KAM declare no conflicts of interest.

23 KSG receives research support from ThermoFisher for the evaluation of new assays for the diagnosis and
24 characterization of viruses and has a royalty generating collaborative agreement with Zeptomatrix.

25

26 Funding Statement: Initial funding for sequencing was generously provided by the New York
27 Community Trust. The work for this publication was also supported by Cooperative Agreement number
28 NU50CK000516, funded by the Centers for Disease Control and Prevention. Its contents are solely the
29 responsibility of the authors and do not necessarily represent the official views of the Centers for Disease
30 Control and Prevention or the Department of Health and Human Services.

31

32 This research has not previously been presented at Scientific Meetings

33

34 Corresponding Author: Alexander C. Keyel, alexander.keyel@health.ny.gov, phone: 518-485-6466, fax:

35 518-473-1326

36

37 **Lay Summary**

38 There are different variants, or types, of the virus that causes COVID-19. These variants may differ in
39 their ability to infect a person, cause severe disease, or evade vaccine protection. From previous studies,
40 we know that vaccines provide substantial protection against the original COVID-19 virus. In this study,
41 we wanted to know how some of the new variants compare to one another in this regard. We found that
42 the Omicron variant could break through vaccine protection more effectively than the Delta variant. The
43 data suggested that Delta may be better able to break through vaccines compared to previous variants,
44 including Alpha, but our sample sizes were low, so this pattern was not statistically significant.
45 Individuals with a booster shot had much stronger protection against Delta compared to their protection
46 against Omicron. We also found that younger people were more likely to be infected with Omicron than
47 Delta.

48

49 **Abstract**

50 Background: Recently emerged variants of SARS-CoV-2 have shown greater potential to cause vaccine
51 breakthrough infections.

52 Methods: A matched cohort analysis used a genomic sequence dataset linked with demographic and
53 vaccination information from New York State (NYS). Two sets of conditional logistic regression analyses
54 were performed, one during the emergence of Delta and another during the emergence of Omicron. For
55 each set, cases were defined as individuals with the emerging lineage, and controls were individuals
56 infected with any other lineage. The adjusted associations of vaccination status, vaccine type, time since
57 vaccination, and age with lineage were assessed using odds ratios (OR) and 95% confidence intervals
58 (CI).

59 Results: Fully vaccinated status (OR: 3, 95% CI: 2.0 - 4.9) and Boosted status (OR 6.7, 95% CI: 3.4 –
60 13.0) were significantly associated with having the Omicron lineage during the Omicron emergence
61 period. Risk of Omicron infection relative to Delta generally decreased with increasing age (OR: 0.964,

62 95% CI 0.950 – 0.978). The Delta emergence analysis had low statistical power for the observed effect
63 size.

64 Conclusions: Vaccines offered less protection against Omicron, thereby increasing the number of
65 potential hosts for the emerging variant.

66

67 Keywords: SARS-CoV-2, COVID-19, Vaccine Breakthrough, Omicron, Delta, Conditional Logistic

68 Regression

69 **Introduction**

70

71 As of June 1, 2022, the SARS-CoV-2 pandemic claimed >6.2 million human lives globally, with >1
72 million deaths in the United States (US) and >68,000 in New York State (NYS) [1]. SARS-CoV-2 has led
73 to substantial agricultural losses [2], poses a risk to wildlife [3,4], and has spilled over into animal
74 populations such as deer [5]. Viral evolution and adaptation has been observed in persistently-infected
75 immunocompromised individuals [6] and animal reservoirs [7].

76

77 Novel variants of SARS-CoV-2 have shown increased rates of transmission and immune evasion [8,9]. In
78 particular, Omicron has evolved a suite of unique mutations which have greatly increased its
79 infectiousness [10], increased its ability to evade current vaccines [8,9], and decreased the effectiveness
80 of convalescent plasma transfusions and monoclonal antibody treatments [11,12]. To a lesser degree, the
81 Delta variant showed some of these same patterns of increased infectiousness [13] and potential for
82 immune evasion compared to earlier strains [14].

83

84 Prior literature has also shown differences in vaccine effectiveness for SARS-CoV-2 lineages associated
85 with variation in vaccine type, time post-vaccination, and patient age. Prior to Delta and Omicron, data
86 have shown reduced neutralizing antibody protection for the Janssen vaccine compared to the Pfizer and
87 Moderna vaccines [15] and slightly stronger protection for Moderna compared to Pfizer [15]. An effect of
88 time post-vaccination has been demonstrated for the Delta variant [14]. Younger individuals were found
89 to be more likely to be infected with Omicron [16,17].

90

91 A matched cohort study was used to test the associations of vaccination status, vaccine type, and time
92 since vaccination with lineage identity during the emergence of new variants of SARS-CoV-2. Analyses
93 were performed for the emergence of the Omicron and Delta variants in NYS.

94

95 **Methods**

96

97 *Data Analysis*

98

99 **Omicron Emergence Analysis** (28 November 2021 and 24 January 2022, Fig. 1)

100 Case-control matching (general approach): In this study design, individuals with Omicron (cases) were
101 matched to individuals with any other lineage (controls). Cases (n = 1439) included B.1.1.529 and all BA
102 sublineages (note: none were classified as BA.2 and BA.3 at the time of the analysis). Controls (n = 728)
103 were all other lineages circulating during the period of Omicron emergence (all sequenced control
104 samples in the matched data set were Delta variant: B.1.617.2 or AY sublineages). The start of the
105 Omicron emergence period was defined by the first detection in the genomic surveillance dataset (even
106 though Omicron was present in the state prior to this date). The emergence period ended when the last
107 non-Omicron case was detected in the surveillance data set. Note that one additional Delta case was
108 identified > 14 days after the last date in the surveillance data set but was excluded on the basis that the
109 sensitivity analysis indicated it would not substantively change the analysis results. Cases were matched
110 to controls on the basis of specimen collection date (± 6 days), economic region (see Fig. 1), age, and sex
111 (Male, Female). Age was matched according to bins (0 – 4, 5 – 11, 12 – 17, 18 – 29, 30 – 49, 50 – 69, 70
112 – 89, >90 years). If an exact match could not be found, mismatches were allowed for sex. One-to-one
113 matching was used, without replacement (i.e., each case was matched to a unique control). The matching
114 was performed in two stages. In the first stage, all possible matches were considered for each case. Cases
115 were then sorted such that the cases with the fewest possible matches would be matched to controls first,
116 in an effort to maximize the sample size.

117

118 Three sets of conditional logistic regressions were performed to estimate Odds Ratios (OR) and 95%
119 confidence intervals (CI). In the first analysis, both vaccinated and unvaccinated individuals were
120 included. Key variables tested were vaccination status (binary: yes/no), booster status (yes/no), vaccine

121 type (none, Pfizer, Moderna, Janssen), time since last vaccination or booster (three factor levels:
122 unvaccinated, vaccinated <90 days, vaccinated \geq 90 days). Time since completion of initial vaccination
123 and time since booster were explored but were less predictive and overlapped strongly with the combined
124 time since last vaccination or booster variable and therefore were excluded.

125

126 For the second analysis, the association between age and lineage was examined, and therefore age was
127 removed as a matching criterion. A conditional logistic regression was performed using age, and
128 interactions of age with the other main variables. No sorting prior to matching was performed for this
129 analysis.

130

131 In the third analysis, cases were again matched to controls based on age, but unvaccinated individuals
132 were excluded in order to allow time since last dose (vaccination series or booster) to be treated as
133 continuous variables. Unvaccinated individuals could not be included in this analysis, as assigning them
134 “NA” would cause these values to be excluded, and 0 would cause these cases to have an unrealistic
135 value.

136

137 Finally, the leverage for each individual data point was tested by removing each case-control pair
138 sequentially, refitting the model and noting the change in the odds ratio (OR). Models were selected using
139 Akaike Information Criterion (AIC) scores [18,19]. Models with lower AIC scores have more model
140 support, and models with $\Delta\text{AIC} > 2$ are generally considered less likely models. As a more complicated
141 nested model can be within ΔAIC of 2, nested models were required to be within $2 * K$ to be considered
142 tied [20]. Note that AIC provides a relative ranking of models but provides no information on the absolute
143 fit of the model. The fit of each model was examined by considering its statistical significance and the OR
144 estimates. Where test results were not significant, the magnitude of the OR was examined. More research
145 was deemed necessary if the estimated OR was large enough to be a public health concern, but 95%
146 confidence intervals included 1.

147
148 All analyses were performed in R 4.1.2 [21] using the package survival for conditional logistic
149 regressions [22,23]. R code is available from www.github.com/akeyel/CLR. The NYS map was created in
150 ArcGIS 10.6 (ESRI, Redlands, CA) using a 2017 Tiger Shapefile from the US Census Bureau [24] and
151 Admin 1 States, provinces 50-m-cultural vector shapefile from Natural Earth Data (accessed 18 March
152 2022) (<https://www.naturalearthdata.com/downloads/50m-cultural-vectors/>)

153
154 **Delta Emergence Analysis** (19 March 2021 and 15 August 2021, Fig. 1)

155 The Delta analyses followed the same methods described above for the Omicron analyses. For the Delta
156 analyses, the focal lineages (cases, n = 603) included B.1.617.2 and all AY sublineages. Non-focal
157 lineages (controls, n = 1816) were all other lineages circulating during the period of Delta emergence
158 (62% B.1.1.7 and Q.4 Alpha, 20% B.1.526 Iota, 3.5% P.1.X Gamma, 1% B.1.351.X Beta, none of the
159 other non-Variant of Concern strains (13.7% combined) exceeded 5%. Booster-related variables were
160 excluded from the analysis as booster shots were not widely available during this period. No analysis was
161 performed on vaccinated only individuals due to low statistical power resulting from a sample size of 12
162 matched pairs.

163
164 **Power Analysis**

165 Statistical power for conditional logistic regression is non-linear, and depends on estimated probabilities.
166 While the analyses above used multiple conditional logistic regression, statistical power was calculated
167 for univariate logistic regression using the WebPower package [25,26] as a simplifying assumption, in
168 order to make the power analyses easier to set up and interpret. Statistical power to detect an OR of 2 with
169 a sample size of 110 was examined for a range of probability values (0.1 – 0.9 for the upper probability,
170 lower probability was adjusted to give an OR of 2). The upper probability value with the highest power
171 (0.7) was then used to assess statistical power for ORs of 2, 3, and 4 for sample sizes between 50 and 350
172 by increments of 50.

173

174 **Data Sources**

175

176 Respiratory swab specimens, positive for SARS-CoV-2 by real-time RT-PCR, were sent from clinical
177 laboratories across NYS for whole genome sequencing at the NYSDOH Wadsworth Center as part of an
178 enhanced genomic surveillance program. Samples were matched to demographics in the Communicable
179 Disease Electronic Surveillance System (CDESS) and vaccination records in the New York State
180 Immunization System (NYSIIS). For persons with multiple collections, only the earliest collected sample
181 with genome available was included.

182

183 Vaccination status was determined for each individual based on dates of sample collection and
184 administration of vaccines. A person was considered “unvaccinated” if the sample was collected prior to
185 any vaccination, “vaccinated” if the sample was collected >14 days after completion of vaccination (first
186 shot of Janssen, second shot of Pfizer or Moderna), and “boosted” if the sample was collected any time
187 after receiving a booster dose, of any vaccine type. Individuals with partial vaccination (sample collected
188 between initial dose and 14 days post completion of vaccination) and those who received a greater
189 number of vaccinations than normal were removed from the study. This study does not apply to
190 individuals who received a 3rd dose as part of their vaccination series (e.g., potentially
191 immunocompromised individuals), as these individuals were removed from the data set (due to different
192 vaccination history and low sample sizes, 58 individuals removed with a 3rd shot less than 135 days from
193 their second shot).

194

195 **Sequencing Methods**

196

197 Whole genome amplicon sequencing of SARS-CoV-2 was performed using a modified version of the
198 Illumina ARTIC protocol (<https://artic.network/ncov-2019>) using ARTIC V3 primers in the Applied

199 Genomics Technology Core at the Wadsworth Center, as previously described [27], with later samples
200 amplified with ARTIC V4 primers.

201
202 For samples of particularly low viral titer, sequencing was performed using the Ion Torrent S5XL
203 sequencer, as previously described [28]. GISAID Accession Sequences are available from
204 www.github.com/akeyel/CLR/GISAID_accession_IDs.csv The first column includes the GISAID
205 accession ID. The subsequent columns indicate whether the ID was used in the respective analyses. Data
206 are coded such that -1 indicates records that were removed prior to analysis, 0 indicates records that met
207 the basic overall study criteria, but that were not matched for a particular analysis, and 1 indicates that the
208 record was included in the analysis.

209

210 **Results**

211

212 *Omicron Emergence*

213 In Analysis 1, >80% of case/control pairs were aged 18 – 69, with the majority from the Capital Region
214 and Mid-Hudson (Table 1, Fig. 1). 8% of control individuals had received a booster while 22% of cases
215 had been boosted. 56.6% of controls and 30% of cases were unvaccinated (Table 1). Sample sizes were
216 177 for Pfizer, 109 for Moderna, and 22 for Janssen. Vaccination (OR 3.1, CI 2.0 – 4.9, $p < 0.001$) and
217 booster status (OR 6.7, CI 3.4 – 13.0, $p < 0.001$) were the variables most associated with an Omicron
218 lineage identity (Table 2, Fig. 2).

219

220 In Analysis 2, when age was removed as a matching criterion, younger age was also predictive of an
221 Omicron infection, with odds of having Omicron generally decreasing as age increased (OR 0.962,
222 CI 0.950 – 0.974, Table 2). Individuals 0-4 years of age had a lower risk of Omicron than predicted by a
223 log-linear age effect (but still much higher risk compared to the 90+ age group), while individuals 18 – 29

224 had a higher risk of Omicron than predicted by a log-linear age term, and the highest risk of any age
225 group. Estimates for OR for vaccination status (OR 4.8, CI 2.8 – 8.1) and booster status (OR 38.5, CI
226 15.9 – 93.2) were higher than in the analysis that matched on age (Table 2).

227
228 In Analysis 3, when only vaccinated individuals were considered, the probability of having Omicron
229 decreased with an increase in the number of days following the last vaccine dose (OR 0.996, CI 0.993 -
230 0.999, Table 2). Vaccine type was also included in the top statistical models, with a borderline significant
231 trend towards reduced odds of Omicron with the Janssen vaccine (OR 0.351, CI: 0.132 - 0.935, relative to
232 Pfizer vaccine; OR 0.388, CI 0.149 - 1.009, relative to any mRNA vaccine, Table 2). AIC scores for
233 alternative statistical models are presented in Table S1.

234

235 *Delta Emergence*

236 In Analysis 1, 75% of case/control pairs were aged 18 – 69, with 89% of case/controls from Finger Lakes,
237 Long Island, and the Mid-Hudson regions (Table 3). 74.5% of controls and 61.8% of cases were
238 unvaccinated (Table 3). Neither vaccine type, time from last vaccination, nor an interaction of the two
239 were significantly related to an increased likelihood of having Delta than any other lineage in the fully
240 matched conditional logistic regression (Table 4). Vaccination status was the ‘best’ model (OR 2.4, CI 0.8
241 – 6.8, $p = 0.08$, Table 4). There was no significant effect of vaccine type ($p = 0.12$), but detected ORs
242 were 2.9 (Pfizer, CI: 0.9 – 8.9), 0.38 (Moderna, CI: 0.04 – 4.2), and 2.0 (Janssen, CI: 0.17 – 23.6).

243

244 The power analysis showed that a sample size of 110 (55 pairs) would have a 15 - 45% chance of
245 obtaining a significant result for an OR of 2 under the simulated probability distributions. A sample size
246 of at least 255 would be needed to have $\geq 80\%$ power for an OR of 2. A sample size of 110 could have up
247 to 78% power to detect an OR of 3 and 93% power for an OR of 4. A sample size of 24 could detect an
248 OR of 22 with 80% power, but would only have 36% power to detect an OR of 4.

249

250 When cases and controls were no longer matched on the basis of age, vaccine type was the ‘best’ model,
251 suggesting that odds of having Delta rather than any other lineage increased by a factor of 7.3 (2.0 - 26.7)
252 for those receiving the Pfizer vaccine relative to unvaccinated individuals. Effects for Moderna (2.0, 95%
253 CI: 0.25 - 17.1) and Janssen (0.46, 95% CI: 0.04 - 4.76) were substantial but not individually significant.
254 When the analysis was restricted to only vaccinated individuals, the sample size was too small for
255 meaningful analysis (12 matched pairs). AIC scores for alternative statistical models are presented in
256 Table S2.

257

258 **Discussion**

259

260 This study adds to the body of evidence supporting immune escape of SARS-CoV-2 by exploring vaccine
261 breakthrough, vaccination status, and time since vaccination in a matched case-control cohort study. As a
262 consequence of the study design, some of the results may seem counter intuitive. For example, while a
263 booster increases protection against Omicron compared to an absence of a booster [16,29], history of a
264 booster was associated with Omicron and not Delta. This is consistent with evidence that suggests that
265 having a booster is less effective for preventing infection with Omicron than with Delta [9,16]. Similarly,
266 vaccine effectiveness has been shown to wane with time [14], therefore it was hypothesized that increased
267 time following vaccination would decrease the odds of being infected with the emergent strain.

268

269 Our analysis of NYS genomic surveillance data yielded results that are consistent with previous research
270 showing an increased probability of breakthrough for Omicron compared to other variants for both
271 vaccinated and boosted individuals [9,11]. In a similar study in Connecticut comparing odds of Omicron
272 vs. Delta infection [9], an OR of ~2 (CI 1.5 - 3.7 or 1.5 - 2.2 depending on time post vaccination) was
273 found for vaccinated individuals and ~3 (1.8 - 4.9) for boosted individuals. These estimates are lower than
274 the estimates from this study of 3.1 (2.0 - 4.9) for vaccinated individuals and 6.7 (3.4 - 13.0) for
275 unvaccinated, but the 95% CIs overlap between the two studies. There is a strong pattern of the emergent

276 strain showing increased ability to breakthrough vaccines compared to other strains circulating at the
277 time. Studies on prior variants of concern have found significant vaccine breakthrough in emergent
278 variants. For example, Kustin et al. 2021 found that Alpha (B.1.1.7) was more likely to show vaccine
279 breakthrough compared to prior strains [30]. Similarly, Tartof et al. 2021 found evidence for increased
280 rates of vaccine breakthrough in Delta (B.1.617.2), although waning vaccine immunity was also a factor
281 in that study [14]. Similarly, Rosenberg et al. 2022 showed an increase in breakthroughs during the Delta
282 emergence period, and suggested this effect existed independently of waning immunity [31].

283
284 Time post vaccination was a statistically significant factor in this study when the analysis was restricted to
285 vaccinated individuals only, with probability of Omicron decreasing with increased time post vaccination.
286 The time post vaccination variable combined individuals who were recently boosted with those who had
287 recently completed their primary series. Adding a variable to indicate booster status did not improve the
288 model fit (Table S1). It is notable that most individuals in this study were more than 3 months post
289 completion of their initial vaccination series. Booster shots were generally more recent, and therefore
290 vaccination status and booster status likely encoded much of the information that would have been
291 conveyed by a time post last dose variable. No time post vaccination effect was detected if the data were
292 coarsely divided into individuals with boosters and individuals without boosters, suggesting more
293 examination of this variable may be necessary. This variable was not found among the top models in the
294 Delta Emergence analysis.

295
296 Younger individuals were found to be more likely to be infected with Omicron than with Delta during the
297 Omicron emergence period, although the data in this study cannot be used to distinguish a physiological
298 basis from a behavioral basis for these age effects. Kahn et al. (2022) found equal age distributions for
299 Delta and Omicron among unvaccinated individuals, but a strong shift towards younger individuals
300 among those vaccinated (however see data table in Accorsi et al. 2022, in the US, where Omicron rates
301 are elevated among both vaccinated and unvaccinated). It is possible that the age bin effects are due to a

302 greater degree of socialization and other behavioral risk factors among 18 – 29 year-olds. For example, in
303 2020, college campus re-openings were associated with increased COVID transmission [32]. With
304 Omicron’s ability to break through vaccinations, college campuses may have increased this age-group’s
305 likelihood of being infected with SARS-CoV-2 (e.g., Wan et al. 2022). The bin effect for pre-school age
306 children (0 – 4 years of age) may represent a reduced level of socialization for this group. This effect,
307 while included in the ‘best’ model identified by the information theoretic approach here, was not
308 statistically significant, so it also may be an artifact of low sample sizes in this age group. Other research
309 has found that vaccines were not equally effective among age groups [33]. Vaccine effectiveness in NYS
310 was very low for 5 – 11 year-olds who received a lower dose (10 µg) of the Pfizer vaccine than for
311 vaccinated individuals aged 12 and up (30 µg dose) [33]. However, the log-linear age effect detected here
312 was not driven by children under 12. When children under 12 were removed from the analysis, the
313 estimated OR changed from 0.962 to 0.957 (CI 0.944 – 0.971), suggesting the magnitude of the effect is
314 greater when young children were removed from the analysis. Larger estimates for vaccination status and
315 booster status were also greater when children under 12 were removed from the analysis (vaccination
316 status OR: 5.4, [CI: 3.1 – 9.7], vaccination plus booster status OR: 43.0 [CI: 17.1 – 108.5]).
317
318 Sample sizes were generally too small to detect robust vaccine type effects. The Janssen vaccine showed
319 borderline significant reduced OR of Omicron relative to the Pfizer vaccine in one statistical model
320 (Table 2, Table S1). This result would be consistent with improved performance against Omicron, or with
321 worse performance of this vaccine against Delta, as has been observed [e.g., 31]. Otherwise, OR estimates
322 showed the potential for substantial differences, but overlapping confidence intervals prevent drawing
323 robust conclusions.
324
325 Low statistical power in this study was due to limited sample sizes, which were constrained by the limited
326 emergence periods and the relatively small percentage of COVID-19 cases that are sequenced. For Delta,
327 the emergence period occurred during a time of reduced sequencing, due to low overall incidence during

328 the summer of 2021 when Delta displaced prior strains (Fig. 1). For Omicron, a larger sequencing effort
329 was made, but the emergence period was considerably shorter due to the rapid dominance of the Omicron
330 variant (Fig. 1). Sample sizes could potentially be increased by expanding the regional scope of the study
331 or incorporating sequencing results from other research labs.

332

333 Only a single matched set was used for each analysis. However, cases were randomly matched to
334 controls, and therefore other matches were possible. This limitation could be overcome by assessing
335 significance with Monte Carlo simulation over the range of possible matches. That said, visual
336 examination of leverage plots based on removing a single pair suggested that the results were generally
337 unlikely to change with the removal of any single data point. The exception is the Delta analysis, where a
338 change in 1-2 data points would change the overall statistical significance of the results (Fig. S1), without
339 much change in the estimated OR.

340

341 **Acknowledgements**

342 The authors thank the Wadsworth Center's Virology Laboratory for processing specimens, the Advanced
343 Genomic Technologies Core for performing next-generation sequencing, and the Bioinformatics Core for
344 sequence analysis. We also thank the New York State clinical laboratories that submitted SARS-CoV-2–
345 positive specimens to Wadsworth for sequencing, as well as all originating and submitting laboratories for
346 their SARS-CoV-2 sequence contributions to the GISAID database.

347

348 **Data Availability**

349 The data set analyzed in this study is not publicly available.

350 **Literature Cited**

- 351
- 352 1. Johns Hopkins Coronavirus Resource Center. Johns Hopkins Coronavirus Resource Center
353 [Internet]. Johns Hopkins University of Medicine; 2022 [cited 2022 Apr 14]. Available from:
354 <https://coronavirus.jhu.edu/>
- 355 2. Mallapaty S. COVID mink analysis shows mutations are not dangerous--yet. *Nature*. Nature
356 Publishing Group; **2020**; 587(7834):340–342.
- 357 3. Delahay RJ, Fuente J de la, Smith GC, et al. Assessing the risks of SARS-CoV-2 in wildlife. *One*
358 *Health Outlook*. **2021**; 3(1):7.
- 359 4. Smyth DS, Trujillo M, Gregory DA, et al. Tracking cryptic SARS-CoV-2 lineages detected in NYC
360 wastewater. *Nature Communications*. Nature Publishing Group; **2022**; 13(1):1–9.
- 361 5. Hale VL, Dennis PM, McBride DS, et al. SARS-CoV-2 infection in free-ranging white-tailed deer.
362 *Nature*. Nature Publishing Group; **2021**; :1–8.
- 363 6. Borges V, Isidro J, Cunha M, et al. Long-Term Evolution of SARS-CoV-2 in an
364 Immunocompromised Patient with Non-Hodgkin Lymphoma. *mSphere*. **2021**; 6(4):e0024421.
- 365 7. Bashor L, Gagne RB, Bosco-Lauth AM, Bowen RA, Stenglein M, VandeWoude S. SARS-CoV-2
366 evolution in animals suggests mechanisms for rapid variant selection. *Proceedings of the National*
367 *Academy of Sciences*. *Proceedings of the National Academy of Sciences*; **2021**;
368 118(44):e2105253118.
- 369 8. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 Vaccine
370 against Omicron Variant in South Africa. *N Engl J Med*. Massachusetts Medical Society; **2022**;
371 386(5):494–496.

- 372 9. Chaguzo C, Coppi A, Earnest R, et al. Rapid emergence of SARS-CoV-2 Omicron variant is
373 associated with an infection advantage over Delta in vaccinated persons. *Med [Internet]*. **2022**; .
374 Available from: <https://www.sciencedirect.com/science/article/pii/S2666634022001386>
- 375 10. Chen J, Wang R, Gilby NB, Wei G-W. Omicron Variant (B.1.1.529): Infectivity, Vaccine
376 Breakthrough, and Antibody Resistance. *J Chem Inf Model*. American Chemical Society; **2022**;
377 62(2):412–422.
- 378 11. Liu L, Iketani S, Guo Y, et al. Striking Antibody Evasion Manifested by the Omicron Variant of
379 SARS-CoV-2. *Nature [Internet]*. **2021**; . Available from: [https://doi.org/10.1038/s41586-021-](https://doi.org/10.1038/s41586-021-04388-0)
380 04388-0
- 381 12. Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-
382 mediated neutralization: Implications for control of the COVID-19 pandemic. *Cell*. **2022**; 185:1–10.
- 383 13. Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused
384 by the SARS-CoV-2 Delta variant. *Nature Communications*. **2022**; 13(1):460.
- 385 14. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up
386 to 6 months in a large integrated health system in the USA: a retrospective cohort study. *The*
387 *Lancet*. Elsevier; **2021**; 398(10309):1407–1416.
- 388 15. Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19 Booster
389 Vaccinations. *N Engl J Med [Internet]*. Massachusetts Medical Society; **2022** [cited 2022 Feb 16]; .
390 Available from: <https://doi.org/10.1056/NEJMoa2116414>
- 391 16. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-
392 19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
393 *JAMA*. **2022**; 327(7):639–651.

- 394 17. Kahn F, Bonander C, Moghaddassi M, et al. Risk of severe COVID-19 from the Delta and Omicron
395 variants in relation to vaccination status, sex, age and comorbidities – surveillance results from
396 southern Sweden, July 2021 to January 2022. *Eurosurveillance* [Internet]. **2022**; 27(9). Available
397 from: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.9.2200121>
- 398 18. Akaike H. A new look at the statistical model identification. *IEEE Transactions on Automatic*
399 *Control*. **1974**; 19(6):716–723.
- 400 19. Burnham KP, Anderson DR. *Model selection and Multimodel inference*. New York: Springer-
401 Verlag; 2002.
- 402 20. Arnold TW. Uninformative parameters and model selection using Akaike’s Information Criterion.
403 *The Journal of Wildlife Management*. **2010**; 74(6):1175–1178.
- 404 21. R Core Team. *R: A language and environment for statistical computing*. R Foundation for Statistical
405 Computing [Internet]. Vienna, Austria; 2021. Available from: <https://www.R-project.org/>
- 406 22. Therneau T. *A Package for Survival Analysis in R* [Internet]. 2021. Available from:
407 <https://CRAN.R-project.org/package=survival>
- 408 23. Therneau TM, Grambsch PM. *Modeling Survival Data: Extending the Cox Model*. New York:
409 Springer; 2000.
- 410 24. US Census Bureau. *TIGER/Line Shapefiles* [Internet]. United States Census Bureau; 2021 [cited
411 2021 Nov 23]. Available from: <https://www.census.gov/geo/maps-data/data/tiger-line.html>
- 412 25. Zhang Z, Mai Y. *WebPower: Basic and Advanced Statistical Power Analysis*. R package version
413 0.7. <https://CRAN.R-project.org/package=WebPower> [Internet]. 2022. Available from:
414 <https://CRAN.R-project.org/package=WebPower>

- 415 26. Demidenko E. Sample size determination for logistic regression revisited. *Statistics in Medicine*.
416 Wiley Online Library; **2007**; 26(18):3385–3397.
- 417 27. Alpert T, Brito AF, Lasek-Nesselquist E, et al. Early introductions and transmission of SARS-CoV-
418 2 variant B.1.1.7 in the United States. *Cell*. **2021**; 184(10):2595-2604.e13.
- 419 28. Plitnick J, Griesemer S, Lasek-Nesselquist E, Singh N, Lamson DM, St George K. Whole-Genome
420 Sequencing of SARS-CoV-2: Assessment of the Ion Torrent AmpliSeq Panel and Comparison with
421 the Illumina MiSeq ARTIC Protocol. *J Clin Microbiol*. **2021**; 59(12):e0064921.
- 422 29. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and
423 death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England:
424 a cohort study. *The Lancet*. Elsevier; **2022**; 399(10332):1303–1312.
- 425 30. Kustin T, Harel N, Finkel U, et al. Evidence for increased breakthrough rates of SARS-CoV-2
426 variants of concern in BNT162b2-mRNA-vaccinated individuals. *Nature Medicine*. Nature
427 Publishing Group; **2021**; 27(8):1379–1384.
- 428 31. Rosenberg ES, Dorabawila V, Easton D, et al. Covid-19 Vaccine Effectiveness in New York State.
429 *N Engl J Med*. Massachusetts Medical Society; **2022**; 386(2):116–127.
- 430 32. Yamey G, Walensky RP. Covid-19: re-opening universities is high risk. *BMJ*. British Medical
431 Journal Publishing Group; **2020**; 370:m3365.
- 432 33. Dorabawila V, Hoefler D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Effectiveness of the
433 BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the
434 Omicron Variant. *medRxiv*. **2022**; :2022.02.25.22271454.

436 **Table 1.** Descriptive statistics for matched cases and controls for the Conditional Logistic Regression for the Omicron emergence period. Presence
 437 (case) or absence (control) of Omicron was used as the basis for matching.

| Demographic group | Analysis 1 (main) | | | | Analysis 2 (age) | | | | Analysis 3 (vax only) | | | |
|-------------------|-------------------|------|-------|------|------------------|------|-------|------|-----------------------|------|-------|------|
| | Control | % | Case | % | Control | % | Case | % | Control | % | Case | % |
| | Count | | Count | | Count | | Count | | Count | | Count | |
| Age | | | | | | | | | | | | |
| 00-04 | 4 | 1.5 | 4 | 1.5 | 9 | 2.9 | 4 | 1.3 | 0 | 0 | 0 | 0 |
| 05-11 | 4 | 1.5 | 4 | 1.5 | 7 | 2.3 | 9 | 2.9 | 0 | 0 | 0 | 0 |
| 12-17 | 11 | 4 | 11 | 4 | 15 | 4.9 | 16 | 5.2 | 3 | 2.3 | 3 | 2.3 |
| 18-29 | 55 | 20.2 | 55 | 20.2 | 39 | 12.6 | 85 | 27.5 | 23 | 17.8 | 23 | 17.8 |
| 30-49 | 95 | 34.9 | 95 | 34.9 | 85 | 27.5 | 95 | 30.7 | 49 | 38 | 49 | 38 |
| 50-69 | 71 | 26.1 | 71 | 26.1 | 96 | 31.1 | 69 | 22.3 | 40 | 31 | 40 | 31 |
| 70-89 | 31 | 11.4 | 31 | 11.4 | 52 | 16.8 | 30 | 9.7 | 14 | 10.9 | 14 | 10.9 |
| ≥90 | 1 | 0.4 | 1 | 0.4 | 6 | 1.9 | 1 | 0.3 | 0 | 0 | 0 | 0 |
| Sex | | | | | | | | | | | | |
| Male | 141 | 51.8 | 147 | 54 | 155 | 50.2 | 153 | 49.5 | 65 | 50.4 | 77 | 59.7 |
| Female | 129 | 47.4 | 123 | 45.2 | 152 | 49.2 | 155 | 50.2 | 63 | 48.8 | 52 | 40.3 |
| Unknown | 2 | 0.7 | 2 | 0.7 | 2 | 0.6 | 1 | 0.3 | 1 | 0.8 | 0 | 0 |

| Region | | | | | | | | | | | | |
|---------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|-----|------|
| Capital Region | 107 | 39.3 | 107 | 39.3 | 121 | 39.2 | 121 | 39.2 | 47 | 36.4 | 47 | 36.4 |
| Central New York | 17 | 6.2 | 17 | 6.2 | 18 | 5.8 | 18 | 5.8 | 10 | 7.8 | 10 | 7.8 |
| Finger Lakes | 7 | 2.6 | 7 | 2.6 | 9 | 2.9 | 9 | 2.9 | 3 | 2.3 | 3 | 2.3 |
| Long Island | 25 | 9.2 | 25 | 9.2 | 27 | 8.7 | 27 | 8.7 | 12 | 9.3 | 12 | 9.3 |
| Mid-Hudson | 42 | 15.4 | 42 | 15.4 | 47 | 15.2 | 47 | 15.2 | 26 | 20.2 | 26 | 20.2 |
| Mohawk Valley | 10 | 3.7 | 10 | 3.7 | 18 | 5.8 | 18 | 5.8 | 4 | 3.1 | 4 | 3.1 |
| New York City | 4 | 1.5 | 4 | 1.5 | 6 | 1.9 | 6 | 1.9 | 1 | 0.8 | 1 | 0.8 |
| North Country | 38 | 14 | 38 | 14 | 39 | 12.6 | 39 | 12.6 | 20 | 15.5 | 20 | 15.5 |
| Southern Tier | 14 | 5.1 | 14 | 5.1 | 16 | 5.2 | 16 | 5.2 | 2 | 1.6 | 2 | 1.6 |
| Western New York | 8 | 2.9 | 8 | 2.9 | 8 | 2.6 | 8 | 2.6 | 4 | 3.1 | 4 | 3.1 |
| Vaccination Status | | | | | | | | | | | | |
| Unvaccinated | 154 | 56.6 | 82 | 30.1 | 175 | 56.6 | 78 | 25.2 | 0 | 0 | 0 | 0 |
| Vaccinated <90 days | 3 | 1.1 | 4 | 1.5 | 3 | 1 | 5 | 1.6 | 2 | 1.6 | 2 | 1.6 |
| Vaccinated >90 days | 115 | 42.3 | 186 | 68.4 | 131 | 42.4 | 226 | 73.1 | 127 | 98.4 | 127 | 98.4 |
| Pfizer Vaccine | 64 | 23.5 | 113 | 41.5 | 69 | 22.3 | 135 | 43.7 | 64 | 49.6 | 82 | 63.6 |
| Moderna Vaccine | 43 | 15.8 | 66 | 24.3 | 49 | 15.9 | 82 | 26.5 | 48 | 37.2 | 41 | 31.8 |
| Janssen Vaccine | 11 | 4 | 11 | 4 | 16 | 5.2 | 14 | 4.5 | 17 | 13.2 | 6 | 4.7 |

| | | | | | | | | | | | | |
|------------------|-----|------|-----|------|-----|------|-----|------|-----|------|----|------|
| Unboosted | 250 | 91.9 | 211 | 77.6 | 281 | 90.9 | 210 | 68 | 108 | 83.7 | 88 | 68.2 |
| Boosted <90 days | 18 | 6.6 | 49 | 18 | 25 | 8.1 | 76 | 24.6 | 18 | 14 | 37 | 28.7 |
| Boosted >90 days | 2 | 0.7 | 9 | 3.3 | 2 | 0.6 | 20 | 6.5 | 1 | 0.8 | 3 | 2.3 |
| Pfizer Booster | 11 | 4.8 | 41 | 15.4 | 13 | 4.5 | 68 | 22.7 | 10 | 7.8 | 33 | 25.6 |
| Moderna Booster | 9 | 3.3 | 17 | 7 | 14 | 4.5 | 28 | 9.4 | 9 | 7 | 7 | 5.4 |

439 **Table 2.** Odds ratios (95% confidence intervals) and parameter significance for models of particular interest for the three Omicron analyses.

| Model | Δ AI | Parameter 1 | Parameter 2 | Parameter 3 | | |
|-----------------------------|-------------|----------------------|-------------------------|----------------------|----------------|------------------|
| C | | | | | | |
| Main Analysis | | | | | | |
| Vaccination Status | 0.00 | Vaccinated | Vaccinated + Boosted | | | |
| | | 3.1 (2.0 -4.9) *** | 6.7 (3.4 – 13.0)*** | | | |
| Vaccine Type | 3.33 | Pfizer | Moderna | Janssen ¹ | | |
| without booster: | | 3.3 (1.9 - 5.6)*** | 3.6 (2.0 – 6.7)*** | 2.0 (0.8 – 5.1) | | |
| with booster | | 10.4 (4.3 – 25.2)*** | 3.8 (1.5 – 9.3)** | | | |
| Age Analysis | | | | | | |
| Vaccination Status + Age | 0.00 | Vaccinated | Vaccinated + Boosted | Age (linear) | Age (0 - 4) | Age (18 - 29) |
| + Age bins | | | | | | |

| | | | | | | |
|----------------------------------|------|---------------------------------------|---------------------------------|--|---------|-------|
| | | 4.8 (2.8 – 8.1)*** | 38.5 (15.9 – 93.2) | 0.964 | 0.250 | 2.0 |
| | | | *** | (0.950- | (0.059- | (1.1- |
| | | | | 0.978) | 1.051) | 3.7) |
| | | | | *** | | * |
| Vaccination Status + Age | 7.41 | Vaccinated | Vaccinated + Boosted | Age | | |
| | | 5.0 (3.0 – 8.3)*** | 34.1 (14.6 – 79.5) | 0.962 (0.950 - 0.974)*** | | |
| | | | *** | | | |
| Vax Only Analysis | | | | | | |
| Janssen + Days Post Dose | 0.00 | Janssen (relative to mRNA vaccine) | | Days post last dose (booster or primary series) | | |
| | | 0.388 (0.149 – 1.009) | | 0.996 (0.993 – 0.999)** | | |
| Vaccine Type + Days Post Dose | 1.18 | Moderna (relative to Pfizer) | Janssen (relative to Pfizer) | Days Post last dose (booster or primary series) | | |
| | | 0.776 (0.448 – 1.344) | 0.351 (0.132- 0.935)* | 0.996 (0.993 – 0.999)** | | |

441 ¹ There was only one boosted individual with an initial Janssen shot, so for statistical reasons this individual was pooled with the unboosted
 442 Janssen individuals. When fit separately, the odds ratio for unboosted Janssen individuals was 1.9 (0.8 – 4.9) with a parameter p value of 0.20, and
 443 the parameter estimate for the single boosted Janssen individual was unreliable.

444 **Table 3.** Descriptive statistics for matched cases and controls for the Conditional Logistic Regression for the Delta emergence period. Presence
 445 (case) or absence (control) of Delta was used as the basis for matching.

| Demographic group | Analysis 1 (main) | | | | Analysis 2 (age) | | | |
|-------------------|-------------------|------|-------|------|------------------|------|-------|------|
| | Control | % | Cases | % | Control | % | Cases | % |
| | Count | | Count | | Count | | Count | |
| Age | | | | | | | | |
| 00-04 | 0 | 0 | 0 | 0 | 3 | 4.5 | 0 | 0 |
| 05-11 | 3 | 5.5 | 3 | 5.5 | 5 | 7.6 | 0 | 0 |
| 12-17 | 5 | 9.1 | 5 | 9.1 | 3 | 4.5 | 4 | 6.1 |
| 18-29 | 11 | 20 | 11 | 20 | 12 | 18.2 | 10 | 15.2 |
| 30-49 | 26 | 47.3 | 26 | 47.3 | 23 | 34.8 | 30 | 45.5 |
| 50-69 | 6 | 10.9 | 6 | 10.9 | 14 | 21.2 | 17 | 25.8 |
| 70-89 | 4 | 7.3 | 4 | 7.3 | 6 | 9.1 | 5 | 7.6 |
| ≥90 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex | | | | | | | | |

| | | | | | | | | |
|---------|----|------|----|------|----|------|----|------|
| Male | 26 | 47.3 | 25 | 45.5 | 28 | 42.4 | 30 | 45.5 |
| Female | 29 | 52.7 | 29 | 52.7 | 38 | 57.6 | 35 | 53 |
| Unknown | 0 | 0 | 1 | 1.8 | 0 | 0 | 1 | 1.5 |

Region

| | | | | | | | | |
|------------------|----|------|----|------|----|------|----|------|
| Capital Region | 3 | 5.5 | 3 | 5.5 | 4 | 6.1 | 4 | 6.1 |
| Central New York | 1 | 1.8 | 1 | 1.8 | 1 | 1.5 | 1 | 1.5 |
| Finger Lakes | 24 | 43.6 | 24 | 43.6 | 27 | 40.9 | 27 | 40.9 |
| Long Island | 11 | 20 | 11 | 20 | 15 | 22.7 | 15 | 22.7 |
| Mid-Hudson | 14 | 25.5 | 14 | 25.5 | 16 | 24.2 | 16 | 24.2 |
| New York City | 0 | 0 | 0 | 0 | 1 | 1.5 | 1 | 1.5 |
| North Country | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Southern Tier | 1 | 1.8 | 1 | 1.8 | 1 | 1.5 | 1 | 1.5 |
| Western New York | 1 | 1.8 | 1 | 1.8 | 1 | 1.5 | 1 | 1.5 |

Vaccination Status

| | | | | | | | | |
|---------------------|----|------|----|------|----|------|----|------|
| Unvaccinated | 41 | 74.5 | 34 | 61.8 | 48 | 72.7 | 35 | 53 |
| Vaccinated <90 days | 7 | 12.7 | 9 | 16.4 | 9 | 13.6 | 9 | 13.6 |
| Vaccinated >90 days | 7 | 12.7 | 12 | 21.8 | 9 | 13.6 | 22 | 33.3 |
| Pfizer | 10 | 18.2 | 18 | 32.7 | 11 | 16.7 | 28 | 42.4 |


| | | | | | | | | |
|---------|---|-----|---|-----|---|-----|---|-----|
| Moderna | 5 | 9.1 | 2 | 3.6 | 4 | 6.1 | 3 | 4.5 |
| Janssen | 1 | 1.8 | 3 | 5.5 | 3 | 4.5 | 1 | 1.5 |

447 **Table 4.** Odds Ratios (95% confidence intervals) and parameter significance for selected models from the
 448 two Delta analyses. Note that none of the main analysis models were statistically significant, as all 95%
 449 confidence intervals for odds ratio estimates overlapped 1.


| Model | Δ AI | Parameter 1 | Parameter 2 | Parameter 3 |
|----------------------|-------------|--------------------|--------------------|---------------------|
| C | | | | |
| Main Analysis | | | | |
| Vaccination Status | 0.00 | Vaccinated | | |
| | | 2.4 (0.8 -6.8) | | |
| Vaccine Type | 1.05 | Pfizer | Moderna | Janssen |
| | | 2.86 (0.92 – 8.94) | 0.38 (0.04 – 4.20) | 1.97 (0.17 – 23.57) |
| Age Analysis | | | | |
| Vaccine Type | 0.02 | Pfizer | Moderna | Janssen |
| | | 7.3 (2.0 – 26.7)** | 2.0 (0.25 – 17.1) | 0.46 (0.04 – 4.76) |

450 Parameter p-values: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

451



452
453 **Fig. 1.** The number of matched case-control pairs used in the Conditional Logistic Regression by analysis
454 for Delta (19 March 2021 – 15 August 2021) and Omicron (28 November 2021 –24 January 2022)
455 emergence periods by New York State Economic Region (see inset). The bars correspond to the order
456 given in the legend, with New York City on top when present, and Long Island on bottom when present.
457 The dashed line was placed to separate the two data sets used in the analyses, with the Delta emergence
458 period on the left and the Omicron emergence period on the right.
459



460

461 **Fig. 2.** Visualization of the fixed effects (excluding stratum-specific effects, which were often strong)
462 from the Omicron Emergence analysis without age matching for the data set used to generate the analysis
463 a) on a log-odds scale and b) on an odds scale. The inset shows Odds from 0 – 25 with greater resolution.
464 Odds of 1 or Log(Odds) of 0 indicate an equal probability of having Omicron or Delta, with increasing
465 values indicative of an increasing probability of having Omicron instead of Delta. Hatched areas indicate
466 +/- 1 SE, and are only shown in (a) for clarity.

467

468 **Table S1.** AIC Results for the Omicron Analyses. Results are for 3 separate conditional logistic
 469 regression analyses (see methods). For all analyses, each case of Omicron was matched to a non-Omicron
 470 control. Minimum AIC scores for each analysis were 330.38, 285.21, and 168.43, with corresponding log-
 471 likelihoods of -163.19, -137.61, and -82.21. Sample sizes were 272, 309, and 129 pairs. AIC scores
 472 SHOULD NOT be compared across different analyses. × indicates an interaction, while + indicates
 473 variables in a model without an interaction term. Full models did not include interaction effects. Best
 474 models are indicated in italics.

| Model | Delta AIC | K | p-value |
|--|--------------|----------|---------------------|
| 1) Conditional Logistic Regression | | | |
| (CLR) | | | |
| <i>Booster Status + Vaccination Status</i> | <i>0.00</i> | <i>2</i> | <i><0.001***</i> |
| Time Post Dose | 2.37 | 2 | <0.001*** |
| Vaccination Status | 4.15 | 1 | <0.001*** |
| Vaccine Type | 5.46 | 3 | <0.001*** |
| Full Model | 6.19 | 6 | <0.001*** |
| Booster Status | 25.41 | 1 | <0.001*** |
| 2) No-age matching CLR | | | |
| <i>Age + Age Bin (18-29) + Age Bin (0 - 4) + Vaccination Status + Booster Status</i> | <i>0.00</i> | <i>7</i> | <i><0.001***</i> |
| Age + Vaccination Status + Booster Status | 7.41 | 3 | <0.001*** |
| Full Model | 11.73 | 7 | <0.001*** |
| Time Post Dose × Age | 29.29 | 5 | <0.001*** |
| Vaccine Type × Age | 43.35 | 7 | <0.001*** |
| Vaccination Status + Booster Status | 57.67 | 2 | <0.001*** |

| | | | |
|---|-------------|---|---------------------|
| Age | 128.36 | 1 | <0.001*** |
| 3) Vaccinated-only individuals CLR | | | |
| <i>Time Post Dose + Janssen</i> | <i>0.00</i> | 2 | <0.001*** |
| Vaccine Type + Time Post Dose | 1.18 | 3 | 0.002** |
| Vaccine Status + Janssen | 1.52 | 2 | 0.002** |
| Time Post Dose | 2.19 | 1 | 0.001** |
| Vaccine Status + Vaccine Type | 2.30 | 3 | 0.003** |
| Booster Status | 2.68 | 1 | 0.002** |
| Full Model | 3.06 | 4 | 0.004** |
| Time Post Dose + Booster Status | 3.51 | 2 | 0.004** |
| Vaccine Type × Time Post Dose | 3.74 | 5 | 0.005** |
| Time Post Dose × Booster Status | 5.51 | 3 | 0.012* |
| Vaccine Type | 6.72 | 2 | 0.021* |
| Janssen | 6.92 | 1 | 0.019* |

475 * p < 0.05, ** p < 0.01, *** p < 0.001

476

477

478 **Table S2.** AIC results for the two Delta analyses. Minimum AIC score was 75.3, and 82.5 with
479 corresponding log-likelihoods of -36.6 and -34.2 for 55 and 66 pairs, respectively.


| Model | Delta AIC | K | p-value |
|---------------------------------|-----------|---|----------------|
| 1) Conditional Logistic | | | |
| Regression (CLR) | | | |
| Vaccination Status | 0.00 | 1 | 0.085 |
| Vaccine Type | 1.05 | 3 | 0.116 |
| Time Post Dose | 1.66 | 2 | 0.191 |
| Full Model | 2.50 | 5 | 0.132 |
| Vaccine Type × Time Post Dose | 6.16 | 7 | 0.267 |
| 2) No-age matching CLR | | | |
| Vaccine Type × Age ¹ | 0.00 | 7 | 0.002** |
| Vaccine Type | 0.02 | 3 | 0.002** |
| Vaccine Type + Age | 1.99 | 4 | 0.005** |
| Vaccination Status | 3.91 | 1 | 0.008** |
| Time Post Dose × Age | 4.68 | 5 | 0.014* |
| Full Model ² | 5.32 | 6 | 0.015* |
| Vaccination Status × Age | 5.97 | 3 | 0.029* |
| Age | 9.75 | 1 | 0.261 |

480 ¹ Model did not converge

481 ² Model converged before all parameters evaluated, some individual parameter estimates should not be
482 used for inference.

483

484



485

486 **Fig. S1.** ‘All’ denotes the model fit including all pairs. The other entries show the model estimated odds
487 ratio and confidence interval if a single pair was removed. If the removal of two pairs had the same
488 estimated effect size, these data points were grouped together, with the number of pairs with similar
489 effects given on the x-axis. For example, the right-most point shows that there were 5 pairs with similar
490 effect sizes. If any one of those pairs were removed, the confidence interval would be approximately at 1.
491 If two of these pairs were removed, the results would likely be statistically significant. That said, there is
492 no scientific basis for removing these pairs from the analysis. The key point is that the statistical
493 significance, but not the median estimate of the odds ratio, was sensitive to the matching process.

494